Have a personal or library account? Click to login
Distribution, lipophilicity and tissue half-life as key factors in sulphonamide clearance from porcine tissues Cover

Distribution, lipophilicity and tissue half-life as key factors in sulphonamide clearance from porcine tissues

Open Access
|Jan 2025

Figures & Tables

Fig. 1.

Total exposure to formulation A active substances (sulphathiazole, sulphamethazine and sulphadimethoxine). A – nonlinear semi-log fit of all observed concentrations (black line) with 99% confidence intervals (dashed lines). Circles represent arithmetic means in one tissue type based on observed concentrations of all active substances. B – variability of sulphathiazole, sulphamethazine and sulphadimethoxine observed concentrations per tissue. MRL – maximum residue limit; I – injection site; K – kidneys; L – liver; M – muscle; F – fat and skin. Bold ticks on the time axis represent the in B represent the start and finish of the designed 10-day withdrawal period
Total exposure to formulation A active substances (sulphathiazole, sulphamethazine and sulphadimethoxine). A – nonlinear semi-log fit of all observed concentrations (black line) with 99% confidence intervals (dashed lines). Circles represent arithmetic means in one tissue type based on observed concentrations of all active substances. B – variability of sulphathiazole, sulphamethazine and sulphadimethoxine observed concentrations per tissue. MRL – maximum residue limit; I – injection site; K – kidneys; L – liver; M – muscle; F – fat and skin. Bold ticks on the time axis represent the in B represent the start and finish of the designed 10-day withdrawal period

Fig. 2.

Total exposure to formulation B active substances (sulphathiazole, sulphamethazine and sulphacetamide). A – nonlinear semi-log fit of all observed concentrations (black line) with 99% confidence intervals (dashed lines). Circles represent arithmetic means in one tissue type based on observed concentrations of all active substances. B – variability of sulphathiazole, sulphamethazine, and sulphacetamide concentrations observed in different tissues. MRL – maximum residue limit; I – injection site; K – kidneys; L – liver; M – muscle; F – fat and skin. Bold ticks on the time axis in B represent the start and finish of the 10-day withdrawal period
Total exposure to formulation B active substances (sulphathiazole, sulphamethazine and sulphacetamide). A – nonlinear semi-log fit of all observed concentrations (black line) with 99% confidence intervals (dashed lines). Circles represent arithmetic means in one tissue type based on observed concentrations of all active substances. B – variability of sulphathiazole, sulphamethazine, and sulphacetamide concentrations observed in different tissues. MRL – maximum residue limit; I – injection site; K – kidneys; L – liver; M – muscle; F – fat and skin. Bold ticks on the time axis in B represent the start and finish of the 10-day withdrawal period

Performance data for the method detecting antibiotic residues in porcine tissues

AnalyteTissueLOD ng/gLOQ ng/gCCα ng/gCCβ ng/gRecovery %Intra-day precision %Inter-day precision %
SulphadimethoxineMuscle1.023.08124.57125.7074.563.494.12
Liver1.173.54128.60129.5096.233.214.56
Kidney1.253.78103.78105.7074.783.525.18
Fat and skin0.902.73119.96120.4477.343.025.96
SulphathiazoleMuscle1.173.55101.01106.2784.414.383.85
Liver1.203.65107.84109.6081.491.584.55
Kidney1.283.90110.03113.7286.679.577.12
Fat and skin1.063.20100.28102.8264.764.365.47
SulphamethazineMuscle1.344.06101.00103.0090.695.236.11
Liver2.728.2585.4587.9195.752.064.23
Kidney1.474.4787.5389,1790.132.613.88
Fat and skin1.083.2888.52100.4592.680.952.45
SulphacetamideMuscle1.544.6765.2368.1148.024.054.41
Liver0.982.9854.8955.3145.484.184.12
Kidney1.313.9779.9682.1259.993.884.88
Fat and skin2.898.7650.8752.2244.961.493.33

Linear regression fit parameters of all observed concentrations per active substance and tissue

TissueY-Intercept (CI)Slope (CI)R2RMSEWP-valueNt
Formulation A
M1nanananananana
M2na5.461 (−4.075e+017– 4.075e+017)0114.60.790.0912No
M3534.4 (−268.5–1337)−41.42 (−114.1–31.26)0.269574.70.8970.3561Yes
K1396.7 (−105.7–899.2)−26.01 (−65.86–13.83)0.645136.950.9520.7292Yes
K2923.3 (511.3–1,335)−66.94 (−101.7–−32.18)0.700173.130.9640.8453Yes
K32,195 (1,351–3,039)−150.9 (−218.2–−83.71)0.6854211.20.8720.1067Yes
L1nanananananana
L2409.1 (249.9–568.3)−25.05 (−37.25–−12.86)0.64650.070.8910.1755Yes
L3394.1 (276.8–511.3)−23.76 (−32.51–−15.02)0.70840.020.9650.854Yes
F1nanananananana
F2659.5 (445.4–873.6)−43.75 (−60.80–−26.69)0.739953.580.9760.9425Yes
F31,442 (987.5–1897)−97.05 (−133.3–−60.83)0.7563113.80.8980.2076Yes
I1nanananananana
I2138.6 (−572.5–849.6)−4.772 (−65.97–56.42)0.0252756.750.950.7127Yes
I3468.9 (−429.0–1,367)−27.92 (−105.2–49.35)0.357671.670.950.7139Yes
Formulation B
M11,320 (899.8–1,740)−92.89 (−127.5–−58.30)nanananana
M2417.8 (299.6–535.9)−26.03 (−35.45–−16.62)0.854176.770.9290.5405Yes
M4nana0.205352.740.8790.336Yes
K11,676 (1,316–2,037)−109.8 (−137.7–−81.91)nanananana
K2421 (353.5–488.5)−31.26 (−37.48–−25.03)0.8525102.30.9020.1961Yes
K4nana0.767829.570.8370.0411No
L12,374 (1,718–3,031)−154.6 (−204.4–−104.8)nanananana
L2na4.859 (−9.685e+016– 9.685e+016)0.7603202.80.9370.4546Yes
L4nana0.9795.0180.8290.1371Yes
F1544.1 (220.6–867.6)−37.01 (−63.72–−10.30)nanananana
F2157 (−15.13–329.1)−7.13 (−22.11–7.852)0.496164.610.9670.8657Yes
F4nanana27.250.9990.9427Yes
I11,037 (401.6–1673)−67.52 (−118.1–−16.89)nanananana
I21,037−67.520.4346159.10.9290.4364Yes
I4nana0.90035.481>0.9999Yes
Language: English
Page range: 101 - 109
Submitted on: Apr 25, 2024
Accepted on: Jan 21, 2025
Published on: Jan 30, 2025
Published by: National Veterinary Research Institute in Pulawy
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2025 Artur Burmańczuk, Monika Osypiuk, Bożena Polska, Dominik Kunicki, Marcin Kocik, Karol Grzęda, Włodzimierz Markiewicz, Oktay Yilmaz, Tomasz Grabowski, published by National Veterinary Research Institute in Pulawy
This work is licensed under the Creative Commons Attribution 4.0 License.